Medical Fund



  • Invests in patented first line pharmaceuticals and biologics as these products tend to have high profit margins and significant barriers to entry.
  • Employs a long-term perspective seeking to capture returns of both intrinsic valuation realization and scientific discovery.
  • The Bio-Pharma sector is relatively insensitive to economic turmoil, while novel research and development imply sustained growth.

Medical Fund Commentary

Read more about the Medical Fund in this commentary.

Medical Fund Fact Sheet

Learn more about the Medical Fund in this fact sheet.

Performance Overview


Portfolio Characteristics

As of September 30, 2014

Portfolio Managers

Paul Abel

Senior Portfolio Manager

Paul joined the firm in 1999 and currently serves as Portfolio Manager to the Kinetics Medical Fund and various other private funds. Paul’s primary...


Daily Performance

As of November 24, 2014
Benchmark Daily NAV One Day Return (%) Month to Date Quarter to Date Year to Date
MEDRX $29.72 0.27% 1.19% 2.59% 12.66%
S&P 500 Index TR $8,180.73 0.29% 2.74% 5.25% 14.03%
Nasdaq Index $4,754.89 0.89% 2.68% 5.82% 13.85%

Total Return (Annualized)

As of September 30, 2014
Benchmark 1YR 3YR 5YR 10YR Since Inception
MEDRX 18.63% 24.26% 14.27% 10.61% 10.23%
S&P 500 Index TR 19.73% 22.99% 15.70% 8.11% 4.87%
Nasdaq Index 19.14% 22.99% 16.18% 9.01% 3.34%

Historical Total Return

1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
MEDRX 33.60% 57.04% -13.77% -29.14% 23.19% 6.96% -0.72% 14.81% 15.47% -20.42% 24.47% 4.30% 5.11% 8.86% 49.25%
S&P 500 Index TR 14.88% -9.10% -11.89% -22.10% 28.68% 10.88% 4.91% 15.79% 5.49% -37.00% 26.46% 15.06% 2.11% 16.00% 32.39%
Nasdaq Index 48.18% -39.29% -21.05% -31.53% 50.01% 8.59% 1.37% 9.52% 9.81% -40.54% 43.89% 16.91% -1.80% 15.91% 38.32%

Class Information

Class Ticker CUSIP 12b-1 Fee Net Expense Ratio Gross Expense Ratio
No Load Class MEDRX 494613102 - 1.39% 2.09%
Advisor A KRXAX 494613847 0.25% 1.64% 2.34%
Advisor C KRXCX 494613755 1.00% 2.14% 2.84%

Fund Statistics

As of September 30, 2014
MEDRX S&P 500 Index TR
Beta 0.69 1.00
Standard Deviation 17.68 15.38
Up Market Capture Ratio 0.92 -
Down Market Capture Ratio 0.59 -
Sharpe Ratio 0.46 0.18
Weighted Avg. Mkt. Cap ($mil) $96,293 $130,658
Median Market Capitalization $2,864 $17,161
Price to Book $4.04 $2.65
Price to Earnings $29.40 $18.43
Return on Equity 14.61% 19.60%

Top 10 Holdings (%)

As of September 30, 2014
Holdings Percent
Biogen Idec, Inc. 9.3%
Bristol-Myers Squibb Company 6.7%
Novartis AG 6.5%
Cubist Pharmaceuticals, Inc. 6.1%
Shire plc 6.0%
Johnson & Johnson 5.8%
Eli Lilly & Company 5.8%
Sanofi 5.7%
Pfizer, Inc. 5.3%
Albany Molecular Research, Inc. 4.8%

Top 10 Industries (%)

As of September 30, 2014
Title Percent
Pharmaceutical and Biotechnology 83.5%
Professional, Scientific, and Technical Services 8.6%
Chemical Manufacturing 7.9%


The Medical Fund is classified as a non-diversified fund. Therefore, the value of its shares may fluctuate more than shares invested in a broader range of industries. You should consult the Fund’s prospectus for a complete list of risks associated with your investment.

You should consider the investment objectives, risks, charges and expenses of the fund carefully before investing.  For a free copy of the fund’s prospectus, which contains this and other information, you may click here or call us at 1-800-930-3828.  You should read the prospectus carefully before you invest.

The Medical Fund No Load Class inception date is 9/30/1999.  Figures include changes in principal value, reinvested dividends and capital gains distributions.  Performance data quoted represents past performance and does not guarantee future results.  Investment return and principal value will vary, and shares may be worth more or less at redemption than at original purchase.  The most recent month-end performance data is listed above, or you may obtain it by calling us at 1-800-930-3828.  Current performance may be lower or higher than the performance data quoted.  Performance data does not reflect the deduction of the sales load or fee which, if reflected, would reduce the performance quoted.  You will be charged a redemption fee equal to 2.00% of the net amount of the redemption if you redeem or exchange your shares 30 days or less after you purchase them.

S&P 500 Index statistics data is based on the iShares S&P 500 Index Fund.

The NASDAQ Composite (NASDAQ) and the Standard & Poor’s 500 Index (S&P 500) each represent an unmanaged, broad-based basket of stocks. They are typically used as a proxy for overall market performance. NASDAQ Composite returns stated above do NOT include reinvested dividends, while the S&P 500 Index returns assume that dividends are reinvested. An investor cannot invest directly in an index.

The Growth of $10,000 chart illustrates the performance of a hypothetical $10,000 investment made in No Load Class shares commencement of operations (9/30/99). It assumes reinvestment of capital gains and dividends. This chart is not intended to imply any future performance.

Holdings are expressed as a percentage of total net investments and may vary over time. Equity holdings are subject to change, and may not be indicative of actual market position due to the use of call and put options.

The Top Industries displayed represent a percentage of the net assets and excludes cash equivalents and other assets in excess of liabilities.

Assets represent the total net assets for the specified portfolio, which includes all fund classes.

Gross expense ratio listed for No-Load Class, Advisor Class A and Advisor Class C Class are referenced in the April 30, 2014 respective prospectus.

The Fund’s adviser, Kinetics Asset Management LLC, has voluntarily agreed to waive management fees and reimburse fund expenses so that net annual fund operating expenses of the No Load Class do not exceed certain levels through May 1, 2015 and may be discontinued at any time by the Fund’s adviser after May 1, 2015.